Maintain Muscle on GLP-1: Genetic & Clinical Strategies

Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Muscle loss during GLP-1 therapy is a recognized clinical concern: studies suggest 25-35% of weight loss can come from lean mass if protein intake and resistance training aren't optimized. Understanding individual metabolic risk factors helps patients and providers design protective strategies from the start.

PlexusDx approaches this challenge through precision wellness: combining clinical nutrition and training principles with genetic context about your FTO, MC4R, and metabolic pathways. This precision-first perspective shifts the conversation from generic protocols to personalized muscle-preservation planning.

Why GLP-1 Users Lose Muscle: Mechanism and Individual Variation

GLP-1 medications reduce appetite and food intake, which naturally decreases overall calories consumed. When caloric deficit exceeds protein synthesis capacity, the body breaks down muscle tissue for energy—a process called catabolism. This occurs even with intentional weight loss.

Not all patients experience muscle loss equally. Baseline metabolic rate, age, existing muscle mass, and genetic factors influencing appetite regulation and nutrient partitioning create wide individual variation. Some patients preserve muscle effectively with moderate intervention; others require intensive strategies despite excellent compliance.

Protein Strategy, Resistance Training, and Behavioral Factors

Evidence supports three evidence-based pillars for muscle preservation on GLP-1: protein intake (typically 1.6–2.2g per kg body weight daily), progressive resistance training 2–4 times weekly, and adequate recovery sleep. These factors work synergistically to maintain muscle protein synthesis during caloric deficit.

Preservation Factor	Clinical Target	Evidence Notes
Daily Protein Intake	1.6–2.2g/kg body weight	Higher end recommended during active GLP-1 use; supports muscle protein synthesis
Resistance Training	2–4 sessions per week	Progressive overload critical; maintains neuromuscular recruitment patterns
Sleep & Recovery	7–9 hours nightly	Supports hormone balance, protein synthesis, and appetite regulation
Carbohydrate Timing	Around training sessions	Supports training performance and recovery; reduces muscle catabolism during exercise

Biomarkers and Genetic Predispositions: Context for Individual Risk

Genetic variants in the FTO gene (rs9939609) and MC4R gene (rs17782313) influence baseline metabolic rate and appetite-satiety signaling. Patients carrying certain variants may experience more pronounced appetite suppression or metabolic shift, potentially increasing relative muscle-loss risk under caloric deficit.

While genetic predisposition doesn't determine outcomes, it can inform baseline expectations and intervention intensity. A provider conversation guided by genetic context helps identify which patients may benefit from higher protein targets, earlier strength training initiation, or closer monitoring during rapid weight loss phases.

Medical Monitoring, Medication Timing, and Provider-Guided Personalization

Muscle preservation on GLP-1 is not a one-time decision—it requires ongoing monitoring. Regular body composition assessment (DXA, bioimpedance, or clinical exam) every 8–12 weeks helps distinguish fat loss from lean mass loss, allowing real-time protocol adjustments by your provider.

Medication type and dosing also matter. Compounded formulations allow dose individualization; some patients preserve muscle better on lower, slower-titrated doses combined with intensive training, while others benefit from standard protocols with enhanced nutrition support. Your provider should guide these decisions based on your baseline health, genetic context, and training capacity.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in FTO and MC4R pathways that may help provide context for your individual metabolic profile and appetite-regulation baseline. This information should be interpreted with a qualified healthcare provider as one factor among many influencing muscle-preservation strategy.

The genetic test does not predict exact medication response or muscle-loss amount—genetics is one layer of a complex picture including age, training history, baseline muscle mass, and nutrition compliance. Rather, predisposition insights can support more informed conversations with your provider about baseline risk and intervention priorities.

When combined with compounded GLP-1 options from PlexusDx (semaglutide from $179/mo or tirzepatide from $229/mo), genetic context enables truly personalized dosing and protocol timing. Your provider can reference your predispositions when optimizing compounded doses, protein targets, and training recommendations for maximum muscle preservation.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.